Navigation Links
FDA Panel to Consider Brain Stimulator for Epilepsy
Date:2/21/2013

By Barbara Bronson Gray
HealthDay Reporter

THURSDAY, Feb. 21 (HealthDay News) - A U.S. Food and Drug Administration advisory panel will weigh on Friday the merits of a new therapy for some people with epilepsy who have seizures that don't respond to medication.

Smaller and thinner than an implantable defibrillator, the battery-powered, programmable device, called the RNS System, is placed just under the skull during surgery. Electrodes reach from the device to the one or two places in the patient's brain that create the abnormal electrical activity that causes seizures. The device works by short-circuiting nerve cells in that area to normalize brain activity before a seizure is triggered.

"This is the first responsive neuro-stimulation system ever designed," said Frank Fischer, president and CEO of Mountain View Calif.-based NeuroPace Inc., which developed the device. "Our long-term results show that patients have a reduction of 50 percent or more in their seizure frequency, compared to baseline, and a lessening of seizure severity."

The device is designed specifically for people aged 18 and older with partial-onset epilepsy, which occurs when one or more fixed locations in a person's brain start the cascade of nerve firing that creates a seizure.

NeuroPace has done two studies involving a total of 256 patients who were monitored for a period of between two and nine years, without any significant problems, according to Fischer.

Epilepsy is a brain disorder in which a person suffers repeated seizures over time.

It affects more than 2 million Americans, according to the Epilepsy Foundation, making it the third most common neurological disorder in the United States, after Alzheimer's and stroke. Seizures are episodes of disturbed brain activity that cause changes in attention or behavior. Brain cells keep firing instead of acting in an organized way. The malfunctioning electrical system of the brain causes surges of energy that can cause a person to have muscle contractions or to black out.

Physicians can modify the programming of the device even after it has been implanted, to reflect a patient's needs over time, Fischer said. They can also observe the brain activity of a patient from a laptop computer in their office -- to help them manage a patient's treatment, he said.

On Friday, members of the FDA panel will listen to a presentation by NeuroPace and hear from members of the public; they will also ask specific questions of company officials.

By the end of the day, the panel is expected to vote on whether to recommend that the device be approved. The FDA does not have to follow the recommendations of its expert panels, but it typically does.

Representatives of the Epilepsy Foundation will also comment on the need for innovative treatments for the disease, but they will not speak for or against approval of the product.

"We're not in a position to evaluate everything that an evaluating committee would be looking at, but we do advocate for access to treatments once they're FDA-approved," explained Angela Ostrom, vice president of public policy and advocacy for the Epilepsy Foundation, based in Landover, Md.

While Fischer said it is too soon to say what the device might cost, comparable systems for heart problems range in price from $30,000 to $35,000, not including the cost of the surgery to implant the device. The battery that powers the device lasts about three years. When it fails, a new device has to be substituted in a 30-to-60-minute outpatient surgical procedure, Fischer said.

Fischer said the company has spent 15 years developing the device.

More information

For more on epilepsy, see the Epilepsy Foundation .

SOURCES: Frank Fischer, president and CEO, NeuroPace, Mountain View, Calif.; Angela Ostrom, vice president, public policy and advocacy, Epilepsy Foundation, Landover, Md.; U.S. Food and Drug Administration documents


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Independent panel to present findings on diagnosing gestational diabetes mellitus
2. Perampanel for epilepsy: No proof of added benefit
3. FDA Panel Votes for Tougher Curbs on Vicodin, Other Painkillers
4. FDA Panel Weighs Tougher Restrictions on Some Prescription Painkillers
5. Panel recommends changing name of common disorder in women
6. 28W [ZT-P3060-28EAE] LED Panel is Announced by Zhongtian Lighting
7. Attempts to correct death panel myth may backfire
8. 18W Normal Ultra Slim Series Panel Light [ZT-P3030-18EAH] from Zhongtian Lighting
9. AxoGen, Inc. to sponsor Educational Symposium and Panel Discussion at 2013 Annual Meetings of American Association for Hand Surgery, American Society for Peripheral Nerve, and American Society for Reconstructive Microsurgery
10. LED Panel Light [ZT-P3012-58EAC] is Released by Zhongtian Lighting
11. A New Dimmable 30W Panel Light from Zhongtian Lighting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Panel to Consider Brain Stimulator for Epilepsy
(Date:2/25/2017)... CA (PRWEB) , ... February 25, 2017 , ... FCPX ... ProSharpen Color tools from Pixel Film Studios. With ProSharpen Color users have total control ... to easily refine their color range. With color spectrum tools users can visually see ...
(Date:2/24/2017)... ... 24, 2017 , ... WHAT: , The New Jersey Tech ... well as advocacy for the state and region‘s technology businesses, hosted their 2017 ... Council's Innovation Forecast event highlights innovation throughout the region from small to large ...
(Date:2/24/2017)... ... , ... In the Health Care IT campaign, Robert Herjavec discusses health IT ... you will be attacked, but when.” However, he and many others involved highlight a ... Improvements in auditing and monitoring have taken security in health care a very long ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have the ability ... total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass ... , With ProGlass Prism users are given the tools and effects to generate ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Indiana Fiber Network ... the company later this year. Dyer started as the Chairman of the Management ... the establishment of the corporation including the recruitment of investor/owners and development of the ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 24, 2017 Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... The Global Empty Capsules Market is poised ... to reach approximately $2.9 billion by 2025. This industry ... on global as well as regional levels presented in the research scope. ...
(Date:2/24/2017)... HARRISBURG, Pa. , Feb. 24, 2017 ... Secretary of Drug and Alcohol Programs Jennifer Smith ... role in providing training for and using naloxone, a ... Mark McCullough , a recovery specialist and overdose ... naloxone by EMS providers. "A significant part ...
(Date:2/24/2017)... Juan Monteverde , founder and managing ... boutique securities firm headquartered at the Empire State Building ... that a class action lawsuit has been filed in the ... Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the "Company") on ... 2015 and December 30, 2016, inclusive (the "Class Period").  ...
Breaking Medicine Technology: